Targets › KATG
2 programs from 2 companies in 3 trials: 2 Phase 1, 1 Phase 2; Infectious disease; next expected readout Apr 2028.
Open in Phaseline: the race on KATG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Isoniazid Enoyl-[acyl-carrier-protein] reductase inhibitor | KATG, INHA | Phase 2 | Tuberculous Meningitis; Tuberculosis | Apr 2028 |
| University Medical Center Groningen | Isoniazid Enoyl-[acyl-carrier-protein] reductase inhibitor | KATG | Phase 1 | Tuberculosis | – |
Tuberculosis (2) Tuberculous Meningitis (1)
small molecule (2)
University Medical Center Groningen (1) National Institute of Allergy and Infectious Diseases (NIAID) (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.